99mTc-labeled duramycin as a novel phosphatidylethanolamine- binding molecular probe

Journal of Nuclear Medicine

Volumn 49, Issue 8, 2008, Pages 1345-1352

  Zhao, Ming ^a   Li, Zhixin ^a   Bugenhagen, Scott ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

imaging; 99mTc; Cardiology; Duramycin; Molecular imaging; Radiopharmaceuticals

Indexed keywords

DURAMYCIN; DURAMYCIN TC 99M; HYDRAZONE DERIVATIVE; LIPOSOME; PHOSPHATIDYLETHANOLAMINE; PHOSPHINE; PHOSPHOLIPID; RADIOPHARMACEUTICAL AGENT; SUCCINIMIDYL 6 HYDRAZINONICOTINATE ACETONE HYDRAZONE; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; BACTERIOCIN; ORGANOMETALLIC COMPOUND; PEPTIDE; TECHNETIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG UPTAKE; GASTROINTESTINAL TRACT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; IN VIVO STUDY; ISOTOPE LABELING; MASS SPECTROMETRY; MOLECULAR IMAGING; MOLECULAR PROBE; MOLECULAR WEIGHT; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIATION DETECTION; RADIOACTIVITY; RAT; STOICHIOMETRY; AMINO ACID SEQUENCE; ANIMAL; BINDING COMPETITION; CHEMISTRY; HUMAN; LEUKEMIA CELL LINE; METABOLISM; MOLECULAR GENETICS; REPERFUSION INJURY; SCINTISCANNING; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BACTERIOCINS; BINDING, COMPETITIVE; HUMANS; JURKAT CELLS; LIPOSOMES; MOLECULAR SEQUENCE DATA; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; ORGANOMETALLIC COMPOUNDS; PEPTIDES; PHOSPHATIDYLETHANOLAMINES; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 48749103305     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.048603     Document Type: Article

References (43)

1. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th ed. New York, NY: Garland Science; 2002.
2. Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res. 1985;26:1015-1035.
3. Bevers EM, Comfurius P, Dekkers DW, et al. Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta. 1999;1439:317-330.
4. Emoto K, Toyama-Sorimachi N, Karasuyama H, et al. Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Exp Cell Res. 1997;232:430-434.
5. Umeda M, Emoto K. Membrane phospholipid dynamics during cytokinesis: regulation of actin filament assembly by redistribution of membrane surface phospholipid. Chem Phys Lipids. 1999;101:81-91.
6. Mills JC, Stone NL, Erhardt J, et al. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. J Cell Biol. 1998;140:627-636.
7. Hayashi F, Nagashima K, Terui Y, et al. The structure of PA48009: the revised structure of duramycin. J Antibiot (Tokyo). 1990;43:1421-1430.
8. Zimmermann N, Freund S, Fredenhagen A, et al. Solution structures of the lantibiotics duramycin B and C. Eur J Biochem. 1993;216:419-428.
9. Marki F, Hanni E, Fredenhagen A, et al. Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and cinnamycin as indirect inhibitors of phospholipase A2. Biochem Pharmacol. 1991;42:2027-2035.
10. Iwamoto K, Hayakawa T, Murate M, et al. Curvature-dependent recognition of ethanolamine phospholipids by duramycin and cinnamycin. Biophys J. 2007;93:1608-1619.
11. Seelig J. Thermodynamics of lipid-peptide interactions. Biochim Biophys Acta. 2004;1666:40-50.
12. Aoki Y, Uenaka T, Aoki J, et al. A novel peptide probe for studying the transbilayer movement of phosphatidylethanolamine. J Biochem (Tokyo). 1994;116:291-297.
13. Machaidze G, Ziegler A, Seelig J. Specific binding of Ro 09-0198 (cinnamycin) to phosphatidylethanolamine: a thermodynamic analysis. Biochemistry. 2002;41:1965-1971.
14. Guder A, Wiedemann I, Sahl HG. Posttranslationally modified bacteriocins: the lantibiotics. Biopolymers. 2000;55:62-73.
15. 1H-NMR1. J Biochem (Tokyo). 1996;119:226-230.
16. Kaletta C, Entian KD, Jung G. Prepeptide sequence of cinnamycin (Ro 09-0198): the first structural gene of a duramycin-type lantibiotic. Eur J Biochem. 1991;199:411-415.
17. 99mTc. Bioconjug Chem. 1997;8:146-154.
18. 99mTc labeling of highly potent small peptides. Bioconjug Chem. 1997;8:621-636.
19. 99mTc using aminocarboxylates as coligands. Bioconjug Chem. 1996;7:63-71.
20. Babich JW, Solomon H, Pike MC, et al. Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J Nucl Med. 1993;34:1964-1974.
21. 99mTc-labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl Med Biol. 1995;22:25-30.
22. 99mTc]chelator-peptide conjugates. Bioconjug Chem. 1996;7:196-202.
23. Kostin S, Pool L, Elsasser A, et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res. 2003;92:715-724.
24. Freude B, Masters TN, Kostin S, et al. Cardiomyocyte apoptosis in acute and chronic conditions. Basic Res Cardiol. 1998;93:85-89.
25. Kim RJ, Chen EL, Lima JAC, et al. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318-3326.
26. Zhu X, Zhang R, Campagna NF, et al. Assessment of reperfused myocardial infarction in the hyper-acute phase with delayed enhancement magnetic resonance imaging. J Cardiovasc Magn Reson. 2006;8:461-467.
27. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction. J Nucl Med. 2006;47:1367-1374.
28. 99mTc-labeled C2A in the area at risk after myocardial ischemia and reperfusion. J Nucl Med. 2007;48:1031-1036.
29. 99mTc-labeled C2A domain of synaptotagmin I in a rat model of ischemia and reperfusion. Nucl Med Biol. 2007;34:907-915.
30. 99mTc-C2A-GST distribution in the area at risk after myocardial ischemia and reperfusion using a compartmental model. Nucl Med Biol. 2007;34:897-905.
31. Zhao M, Beauregard DA, Loizou L, et al. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med. 2001;7:1241-1244.
32. 99mTc-labeled C2A domain of synaptotagmin I in a porcine-ischemia reperfusion model. Nucl Med Biol. 2007;34:917-923.
33. Jung HI, Kettunen MI, Davletov B, et al. Detection of apoptosis using the C2A domain of synaptotagmin I. Bioconjug Chem. 2004;15:983-987.
34. Krishnan AS, Neves AA, de Backer MM, et al. Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology. 2008;246:854-862.
35. 99mTc-annexin V. J Nucl Med. 2005;46:807-815.
36. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet. 2000;356:209-212.
37. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA. 1998;95:6349-6354.
38. Ohtsuki K, Akashi K, Aoka Y, et al. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med. 1999;26:1251-1258.
39. Petrovsky A, Schellenberger E, Josephson L, et al. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res. 2003;63:1936-1942.
40. Lahorte CMM, VanderHeyden JL, Steinmetz N, et al. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging. 2004;31:887-919.
41. Sosnovik DE, Schellenberger EA, Nahrendorf M, et al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn Reson Med. 2005;54:718-724.
42. Huber R, Romisch J, Paques EP. The crystal and molecular structure of human annexin V, an anticoagulant protein that binds to calcium and membranes. EMBO J. 1990;9:3867-3874.
43. Sutton RB, Davletov BA, Berghuis AM, Sudhof TC, Sprang SR. Structure of the first C2 domain of synaptotagmin I: a novel Ca2+/phospholipid-binding fold. Cell. 1995;80:929-938.